Aktis Oncology, Inc.
NASDAQ:AKTSBiotechnology
Healthcare
$16.10 +0.47%
+$0.11 today
- Market cap
- $865.32M
- Beta
- 1.10
- P/E (TTM)
- -28.7
- EPS (TTM)
- -$0.82
52W Low $14.72High $29.16
Volume 0.44M
Average 0.33M
Income Statement
Follow revenue through to earnings.
Revenue
$6.50M
FY 2025 · Annual
+336.9% YoYOperating Income
-$74.68M
FY 2025 · Annual
Net Income
-$63.73M
FY 2025 · Annual
Income Statement
USD
Metric | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|
| Revenue | 0 | 0 | 1.49M | 6.5M |
| Cost of Revenue | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 1.49M | 6.5M |
| Gross Margin | — | — | 100.0% | 100.0% |
| Research & Development | 14.3M | 25.92M | 40.95M | 67.45M |
| Selling, General & Admin | 5.11M | 7.68M | 11.31M | 12.6M |
| Operating Expenses | 19.76M | 34.79M | 53.54M | 81.18M |
| Depreciation & Amortization | 445K | 1.2M | 1.58M | 2.33M |
| EBITDA | (17.48M) | (27.45M) | (42.41M) | (61.4M) |
| EBITDA Margin | — | — | -2851.7% | -945.1% |
| Operating Income | (19.76M) | (34.79M) | (52.05M) | (74.68M) |
| Operating Margin | — | — | -3500.3% | -1149.5% |
| Interest Income | 1.65M | 5.38M | 8.1M | 11.01M |
| Interest Expense | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 1.84M | 6.15M | 8.07M | 10.95M |
| Income Before Tax | (17.93M) | (28.64M) | (43.98M) | (63.73M) |
| Pre-Tax Margin | — | — | -2957.6% | -980.9% |
| Income Tax Expense | 0 | 0 | 0 | 0 |
| Net Income | (17.93M) | (28.64M) | (43.98M) | (63.73M) |
| Net Margin | — | — | -2957.6% | -980.9% |
| EPS (Basic) | (0.51) | (0.82) | (1.26) | (1.19) |
| EPS (Diluted) | (0.51) | (0.82) | (1.26) | (1.19) |
| 34.86M | 34.86M | 34.86M | 52.52M | |
| 34.86M | 34.86M | 34.86M | 52.52M |
AKTS Earnings Waterfall · TTM
NASDAQ:AKTS · Revenue to Net Income
No earnings data available.
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 8-K | Current report | Nov 12, 2026 | |
| 10-Q | Quarterly report | Nov 12, 2026 | |
| 4 | Statement of changes in beneficial ownership | Sep 24, 2026 | |
| 10-Q | Quarterly report | Aug 13, 2026 | |
| 8-K | Current report | Aug 13, 2026 |
How much revenue does AKTS generate?
Aktis Oncology, Inc. (AKTS) reported $6.50M of revenue in fiscal 2025.
Is AKTS profitable?
Aktis Oncology, Inc. (AKTS) reported -$63.73M of net income, with a net margin of -980.9%.
Continue the stock analysis
Jump to another research area for this company.